We have been diligently investigating all reports in an effort to determine contributing factors. We are confident that our products, when used according to label directions, are safe and effective, she said. However, we have taken this step because of the importance of these issues to our customers and their patients.
Patient safety is our number one concern.
Such changes could be designed to include improved directions for use and additional warnings and precautions concerning the potential for serious corneal adverse events. The adverse events appear to be more prevalent in patients with corneal problems, including those with dry eye or corneal epithelial defects. In addition, the association of adverse events with particular subsets of patients and the extensive concomitant use with other medications, particularly topical steroids, are also not fully known. Alcon Laboratories is a member of the Alcon group, the global leader in the research, development, manufacture and marketing of ophthalmic products, including surgical instruments and accessory products, intraocular lenses, prescription drugs and contact lens care solutions. The Alcon group is wholly-owned by Nestl S.A. Founded in Fort Worth, Texas in 1947, the Alcon group now employs 10,000 individuals around the world.